Search results
Results from the WOW.Com Content Network
Gadodiamide is a contrast medium used for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. It provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS).
Antiretroviral drugs are used to manage HIV/AIDS. Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden. Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.
Gadobutrol should be administered intravenously by medical professionals only. Sterile techniques must always be used when preparing and administering the injection. When compared to other GBCAs, Gadobutrol is available in a more concentrated form (1 mmol/mL) to alleviate a high volume of administration. The recommended dose is 0.1 mL/kg body ...
Modern tablet presses reach output volumes of up to 1,700,000 tablets per hour. These huge volumes require frequent in-process quality control for the tablet weight, thickness and hardness. Due to efforts to reduce rejects rates and machine down-time, automated tablet testing devices are used on-line with the tablet press or off-line in the IPC ...
Gadoteridol is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance . [ 3 ] Gadoteridol was first approved for use in the United States in 1992.
It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd 3+), and is used in form of the meglumine salt (gadoterate meglumine). [ 4 ] [ 5 ] The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI , which is the source of its clinical utility.
Gadopiclenol was approved for medical use in the United States in September 2022 by the Food and Drug Administration. [2] [12]In October 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Elucirem, intended for contrast-enhanced ...
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.